Sponsor content
336 result(s) found, displaying 91 to 100
-
Designation or determinationProvisional determination
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CALQUENCE acalabrutinib (as maleate) 100 mg film-coated tablet blister pack.
-
Australian public assessment report (AusPar)Imjudo (tremelimumab) is approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian public assessment report (AusPar)Imfinzi (Durvalumab) has been approved for the treatment of unresectable hepatocellular carcinoma.
-
Australian public assessment report (AusPar)Andexxa (andexanet alfa) is provisionally approved for adult patients treated with a direct factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BREZTRI AEROSPHERE 160/7.2/5 budesonide 160 mcg/glycopyrronium 7.2 mcg/formoterol fumarate dihydrate 5 mcg per actuation inhalation pMDI (DFP-EvoCap).
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SAPHNELO anifrolumab 300 mg concentrated injection vial.
-
Prescription medicine decision summaryWe have provisionally approved Andexxa (andexanet alfa) for patients treated with a direct factor Xa inhibitor, when reversal of anticoagulation is needed.